Genotypic infection endpoint analysis to understand efficacy and escape potential of the malaria monoclonal antibody CIS43LS

Early-phase trials of candidate malaria interventions in endemic areas often use "time-to-first" infection as a primary efficacy endpoint. This approach does not assess infection risk after the initial infection, and its censoring of trial participants after their first infection can introduce bias by removing more high-risk participants from control than treatment arms over time. Efficacy estimate precision may also decline as risk set size decreases. Here we assessed the utility of genotyping all infections in an intervention trial to determine the total infection incidence in each participa

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.